COCRYSTAL PHARMA NEW O.N. Cash Flow-to-Debt Ratio
COCRYSTAL PHARMA NEW O.N. cash flow-to-debt ratio. COCRYSTAL PHARMA NEW O.N. (8CC) has a Cash Flow-to-Debt Ratio of -0.51x as of December 2025, meaning its operating cash flow of €-1.74 Million could theoretically repay -1% of its total liabilities (€3.38 Million) in one year. See COCRYSTAL PHARMA NEW O.N. (8CC) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of COCRYSTAL PHARMA NEW O.N. (2021–2025)
Cash flow-to-debt ratio of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. Historical debt coverage capacity for COCRYSTAL PHARMA NEW O.N. across 5 annual periods. Also explore 8CC net assets growth trend to track the company's year-over-year net asset growth rate.
COCRYSTAL PHARMA NEW O.N. Cash Flow-to-Debt Ratio by Year (2021–2025)
COCRYSTAL PHARMA NEW O.N. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for COCRYSTAL PHARMA NEW O.N.. For the full cash flow conversion analysis, see 8CC cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.42x | €-8.19 Million | €3.38 Million | ▲ +42.2% |
| 2024 | -4.19x | €-16.48 Million | €3.93 Million | ▼ -39.3% |
| 2023 | -3.01x | €-14.67 Million | €4.88 Million | ▲ +82.1% |
| 2022 | -16.84x | €-21.43 Million | €1.27 Million | ▼ -144.0% |
| 2021 | -6.90x | €-12.72 Million | €1.84 Million | — |